AxoGen Reports Strong Q1 2026 Revenue Growth and Raises Full-Year Guidance
AxoGen reported Q1 2026 revenue of $61.5 million, a 26.6% increase year-over-year, and raised its full-year 2026 revenue guidance to at least $270 million. The company also achieved adjusted EBITDA of $5.7 million and is now effectively debt-free with $103.6 million in cash.
Tickers: $AXGN
Topics: Debt Management Earnings Guidance FDA Approval Free Cash Flow Payer Coverage Revenue Growth